Orthokeratology Lens Market Forecasts from 2023 to 2028

The orthokeratology lens market is expected to grow at a CAGR of 7.6% from US$647.256 million in 2021 to US$1,081.121 million in 2028.

An orthokeratology lens is used to correct refractive errors by reshaping the cornea to improve vision. The growing prevalence of refractive errors and by-birth vision impairment is propelling the orthokeratology lens market. Further, the technological advancements and products launched by the major market players are expected to boost the orthokeratology lens market. Additionally, the myopia problem in the aging population is rising with the growing rate of aging population is further contemplated to widen the orthokeratology lens market size.

Higher Prevalence of Refractive Errors

There is an increasing prevalence of refractive errors such as myopia, astigmatism, and hyperopia. According to WHO, nearly 2.2 billion people had myopia or hyperopia in 2022 and 1 million out of this could be prevented. According to the International Myopia Institute, around half of the population will have myopia which is around 5 billion people, by 2050. Moreover, myopia is becoming the leading cause of permanent blindness worldwide. Myopia can be corrected with timely treatment and precautions. The growing prevalence of refractive errors is pushing the demand for orthokeratology lenses thereby propelling the orthokeratology lens market size.

Multiple Advantages of Orthokeratology Lens

Orthokeratology lens is gaining popularity due to its multiple associated benefits and comfort as compared to other treatments. The maximum improvement with an orthokeratology lens can be achieved in three weeks and some patients get the improvement in just a few days. It ultimately provides 20/40 vision to the patients by optimizing vision correction. Moreover, the other treatment methods have side effects, for example, 20% of people treated with LSAIK suffer contrast and face glare. It provides additional comfort for athletes and children as it usually does not involve usage during the daytime which makes the operating hours better. The diverse advantages of the orthokeratology lens are anticipated to boost the orthokeratology lens market.

Consumers Preferring Non-Surgical Vision Treatment

Hyperopia is generally present in children from birth and runs in families. The patients are preferring surgical-free treatment and orthokeratology is a non-surgical treatment that enables people to leave the glasses permanently or at least in the daytime. There are very less options available for refractive errors in children which is also leading to the preference shift towards orthokeratology lens thus boosting the orthokeratology lens market. The survey conducted by Taylor & Francis Online in August 2019 for exotropia in China revealed that more than half of the respondents prefer non-surgical methods for exotropia treatment.

Aging Population

The aging population is the leading cause of vision impairment which can be corrected by an orthokeratology lens. Older adults may lose the ability to see up close and ability to distinguish between colors. The American Academy of Ophthalmology recommends regular eye checkups for people aged 65 or above with an initial checkup at 40 years of age. The ageing population is growing, for instance, the proportion of people aged 60 years or above is increasing at a higher rate than past. In 2019, people aged 60 years or above accounted for 1 billion which is estimated to reach 1.4 billion by 2030 and 2.1 billion by 2050 according to WHO. The prevalence of the ageing population is contemplated to boost the orthokeratology lens market.

Opportunities in the Market

The rising refractive error cases coupled with the aging population provide a great opportunity to enter the orthokeratology lens market. The government regulation and approval of the orthokeratology lens further provide an opportunity. For instance, the Dermalite OK lens developed by Cooper Vision got CE approval from European Union in May 2021 to slow myopia progression. The technological developments and research initiatives are anticipated to boost the orthokeratology lens market thereby providing a phenomenal opportunity for market expansion.

Restraints in the Market

Apart from the multiple advantages and consumer preferences, there are some restraining factors which is expected to limit the orthokeratology lens market. The higher cost associated with orthokeratology is limiting the market growth. For instance, the orthokeratology treatment may range between USD 1200 and USD 2000, US$1,000 in general errors while the cost in cases of higher refractive error may reach up to USD 4000 in 2021 as per the CareCredit.

North America in an Expected Dominant Market

The North-American region is expected to dominate the orthokeratology lens market during the forecast period. Various factors attributed to such a dominant share are the ageing population and the higher prevalence of refractive error in the region. For instance, the prevalence rate of refractive error is 42% in America which is nearly doubled in the last three decades as per the International Myopia Institute. Moreover, the technological advancements and presence of market leaders such as Euclid Systems, Cooper Vision, and Johnson & Johnson Vision are further expected to aid the orthokeratology lens market in the region.

Orthokeratology Lens Market Players

• Euclid Systems Corp is a myopia management orthokeratology company providing solutions since 1975. It designs lenses for children to reshape the cornea while they sleep. Moreover, it provides certification to practitioners in myopia management through Euclid Ortho-K.
• Bausch and Lomb offer contact lenses, lens care products, intraocular lenses, and prescription pharmaceuticals. The company supplies XO2 Orthokeratology solutions.
• CooperVision is one of the leading companies dealing in contact lenses. The company provides 1 day and reusable contact lenses with featured products such as the Aspire™ PRO family and Aspire™ AIR family.

Key Market Developments

• In May 2023, Menicon Co, Ltd. launched an orthokeratology lens called Menicon Z Night in China. It is customizable depending on the corneal shape data and it will be sold under the Itabashi Medical Co., Ltd. which is a subsidiary of Menicon Group.
• In January 2022, Johnson & Johnson Vision launched Acuvue Abiliti™ to control children's myopia in Singapore. It is a new brand exclusively designed for myopia management and the solutions provided seamlessly fit into the children's lifestyle.
• In May 2021, Euclid Systems launched a new Euclid MAX Ortho-K lens in the US. It is enabled with a Hyper Dk of 180 while maintaining lens stability. Moreover, it is approved by FDA and in the survey by the company, 100% of the respondents said to recommend Euclid Max to their patients.

Segmentation:

By Product Type

• Day-time Ortho-K Lenses
• Overnight Ortho-K Lenses

By Indication

• Myopia
• Presbyopia
• Hypermetropia
• Astigmatism

By Distribution Channel

• Hospitals
• Optometry Clinics
• Ophthalmology
• Others

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others